Skip to main content

Table 2 Baseline clinical characteristics of the participants, dead vs alive in the follow-up

From: Observed versus predicted cardiovascular events and all-cause death in HIV infection: a longitudinal cohort study

 

All HIV

n = 369

Dead

N = 62

Alive

N = 307

Univariate

p

Age, years

43.0 ± 9

46.4 ± 8

42.3 ± 9

0.001

Male, n (%)

232 (62.9)

44 (71.0)

188 (61.2)

0.148

Body mass index, kg × m−2

24.2 ± 4

24.0 ± 4

24.2 ± 4

0.718

IDU risk factor, n (%)

101 (27.4)

30 (48.4)

71 (23.1)

<0.001

Cigarette smoking, n (%)

199 (53.9)

40 (64.5)

159 (51.8)

0.067

Systolic blood pressure, mm Hg

130.5 ± 17

130.7 ± 20

130 ± 16

0.91

Total cholesterol, mg/dL

181 ± 48

170 ± 47

183 ± 47

0.052

High-density lipoprotein cholesterol, mg/dL

55 ± 20

49 ± 22

56 ± 19

0.218

Diabetes, n (%)

27 (7.3)

6 (9.1)

21 (6.8)

0.434

CDC stage C3, n (%)

105 (28.5)

32 (51.6)

73 (23.8)

<0.001

Baseline CD4 lymphocyte mm3

501 ± 309

393 ± 331

523 ± 300

0.005

Baseline HIV-RNA < 50 copies/mL, n (%)

256 (69.4)

41 (46.1)

215 (70.0)

0.543

Nadir CD4 lymphocyte mm3

181 ± 158

141 ± 130

189 ± 162

0.012

Zenit HIV-RNA, copies/mL (log10)

5.0 ± 0.8

5.0 ± 0.6

5.0 ± 0.8

0.620

Hepatitis C infection, n (%)

111 (30.2)

29 (46.8)

82 (26.8)

0.002

  1. Values are mean ± SD
  2. CVD cardiovascular disease, SCORE systematic coronary risk evalutation, CDC Centers for Disease Control and Prevention, IDU injecting drug user